BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol 2021;11:803050. [PMID: 35004328 DOI: 10.3389/fonc.2021.803050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Wang Q, Ying Q, Zhang X, Ye T, Chen K, Li G. A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells. Marine Drugs 2023;21:77. [DOI: 10.3390/md21020077] [Reference Citation Analysis]
2 Cousin S, Toulmonde M, Kind M, Guegan JP, Bessede A, Cantarel C, Bellera C, Italiano A. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Exp Hematol Oncol 2022;11:104. [PMID: 36474303 DOI: 10.1186/s40164-022-00338-2] [Reference Citation Analysis]
3 Cejuela M, Vethencourt A, Pernas S. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Curr Oncol Rep 2022;24:1801-19. [PMID: 36255603 DOI: 10.1007/s11912-022-01339-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Front Oncol 2022;12:919072. [DOI: 10.3389/fonc.2022.919072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]